

THE UNIVERSITY OF MICHIGAN  
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Project Agreements with the University of Michigan

Action Requested: Authorization to enter into or amend Agreements

Preamble:

Statutory conflicts of interest situations were identified by the Office of Research and Sponsored Projects while reviewing Proposal Approval Forms that then triggered a review by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. Plans for management of the possible risks associated with the conflicts of interest will be developed and approved by the Board and/or Committee and may require agreement by the parties involved at time of award.

These proposed project (e.g., research, sponsored activity, and/or subcontract) agreements (“Agreement”) and/or amendments to Agreements (“Amendments”) fall under the State of Michigan Conflict of Interest Statute because University of Michigan (“University”) employees have activities, relationships, or interests in the companies as described in Attachment A. The law permits such Agreements provided they are disclosed to the Board of Regents (“Regents”) of the University and approved in advance by a 2/3 vote.

Agreement Terms:

The terms of the Agreements and/or Amendments conform to University policy. The funding support will not exceed the amount reported in Attachment A for each Agreement and/or Amendment. Since projects are often amended, these Agreements and/or Amendments include provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreements and/or Amendments will provide support of investigator’s effort to use their expertise and University laboratories, as well as other University resources, to execute the projects as reported in Attachment A.

Recommendations:

These matters have been reviewed and approved by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreements and Amendments were negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into or amending the Agreements referenced in Attachment A.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Rebecca Cunningham', written in a cursive style.

Rebecca Cunningham  
Vice President for Research

February 2023

## Attachment A

### Project #1

<b>Research Agreement between the University and Beijing Zenithnano Technology Co., Ltd. Reviewed by the UMOR Conflict of Interest Review Committee</b>	
<b><u>Project Information</u></b>	
<b>Title:</b> Toward self-assembly of $\mu$ LED for display by electrostatic and entropic interactions	<b>U-M Project ID:</b> 23-PAF03521
<b>Direct Sponsor:</b> Beijing Zenithnano Technology Co., Ltd.	
<b>Principal Investigator/Department:</b> L Jay Guo, Electrical Engineering and Computer Science–Electrical and Computer Engineering (EECS-ECE) Division	
<b>Project Duration:</b> One (1) Year	<b>Funding Support:</b> \$100,000
<b>Purpose:</b> The purpose of this project is to study the feasibility of fluidic assembly of micron-scale micro-LEDs with high efficiency and high throughput.	
<b><u>University Employee; University Title; Relationship with Beijing Zenithnano Technology Co., Ltd.</u></b> <ul style="list-style-type: none"><li>• L Jay Guo; Professor, EECS-ECE Division; Partial Owner</li></ul>	

### Project #2

<b>SBIR Phase II Subcontract Agreement between the University and EVOQ Therapeutics, Inc. (formerly known as EVOQ Therapeutics LLC) Reviewed by the UMOR Conflict of Interest Review Committee</b>	
<b><u>Project Information</u></b>	
<b>Title:</b> New Approach for Immune Modulation Against T1D	<b>U-M Project ID:</b> 23-PAF00770
<b>Direct Sponsor:</b> EVOQ Therapeutics, Inc.	<b>Prime Sponsor:</b> National Institutes of Health
<b>Principal Investigator/Department:</b> James Moon, Pharmaceutical Sciences	
<b>Project Duration:</b> Two (2) Years	<b>Funding Support:</b> \$300,000
<b>Purpose:</b> The purpose of this project is to develop new technologies for inducing immune tolerance against type-I diabetes (T1D).	
<b><u>University Employee; University Title; Relationship with EVOQ Therapeutics, Inc.</u></b> <ul style="list-style-type: none"><li>• James Moon; Professor, Pharmaceutical Sciences; Partial Owner</li><li>• Vishalakshi Krishnan; Program Officer-The Center for Research in Complex Genetics; Employee</li><li>• Anna Schwendeman; Professor, Pharmaceutical Sciences; Partial Owner</li></ul>	

### Project #3

**STTR Phase I/II Subcontract Agreement between the University and GeneToBe, LLC  
Reviewed by the Medical School Conflict of Interest Board**

**Project Information**

**Title:** Genome Editing Therapy for Usher Syndrome Type 3 - STTR R41/R41-Fast Track

**U-M Project ID:** 23-PAF00749

**Direct Sponsor:** GeneToBe, LLC

**Prime Sponsor:** National Institutes of Health

**Principal Investigator/Department:** Dongshan Yang, Internal Medicine–Cardiology

**Project Duration:** Three (3) Years

**Funding Support:** \$1,265,976

**Purpose:** The purpose of this project is to develop a gene editing therapy for Usher Syndrome Type 3A (USH3A) using a large animal model.

**University Employee; University Title; Relationship with GeneToBe, LLC**

- Yuqing Chen; Professor, Cardiovascular Medicine; Partial Owner
- Jie Xu; Research Associate Professor, Internal Medicine–Cardiology; Partial Owner

### Project #4

**Other Sponsored Activity Agreement between the University and Lynx Dx, Inc.  
Reviewed by the Medical School Conflict of Interest Board**

**Project Information**

**Title:** Validation of My Prostate Score

**U-M Project ID:** 23-PAF00768

**Direct Sponsor:** Lynx Dx, Inc.

**Principal Investigator/Department:** John Wei, Urology

**Project Duration:** Two (2) Years

**Funding Support:** \$47,570

**Purpose:** The purpose of this activity is to send prostate cancer antigen (PCA) samples to Lynx Dx, Inc. for technical validation and calibration of a urine diagnostic test for prostate cancer by measuring levels of prostate cancer specific genes with a multiplexed qPCR assay.

**University Employee; University Title; Relationship with Lynx Dx, Inc.**

- Arul Chinnaiyan; Professor, Pathology; Partial Owner

### Project #5

**SBIR Phase II Subcontract Agreement between the University and Mekanistic Therapeutics, Inc.  
Reviewed by the Medical School Conflict of Interest Board**

**Project Information**

**Title:** SBIR PH II Leopold: Development of MTX-531 for Treatment of Squamous Head and Neck Cancers

**U-M Project ID:** 23-PAF03589

**Direct Sponsor:** Mekanistic Therapeutics, Inc.

**Prime Sponsor:** National Institutes of Health

**Principal Investigator/Department:** Judith Leopold, Radiology

**Project Duration:** Two (2) Years

**Funding Support:** \$209,718

**Purpose:** The purpose of this project is to bolster preclinical support for the clinical advancement of the drug MTX-531 for the treatment of squamous head and neck cancers (HNSCC).

**University Employee; University Title; Relationship with Mekanistic Therapeutics, Inc.**

- Judith Leopold; Research Professor, Radiology; Partial Owner
- Christopher Whitehead; Chemist Staff Specialist, Radiology; Partial Owner
- Mary Stewart; Contract and Grant Specialist, Radiology; Partial Owner

### Project #6

**SBIR Phase II Subcontract Agreement between the University and MONDE Wireless, Inc.  
Reviewed by the UMOR Conflict of Interest Review Committee**

**Project Information**

**Title:** N-polar GaN HEMTs on scalable substrates for mm-wave applications

**U-M Project ID:** 22-PAF04846

**Direct Sponsor:** MONDE Wireless, Inc.

**Prime Sponsor:** Office of Naval Research, Defense, Department of-Navy, Department of the-Subcontracts

**Principal Investigator/Department:** Elaheh Ahmadi, EECS-ECE Division

**Project Duration:** Three (3) Years, Five (5) Months

**Funding Support:** \$42,132

**Purpose:** The purpose of this project is to perform calibration/validation growths and characterization for the regrowth of highly doped ohmic contacts for N-polar GaN structures supplied by MONDE Wireless, Inc.

**University Employee; University Title; Relationship with MONDE Wireless, Inc.**

- Elaheh Ahmadi; Assistant Professor, EECS-ECE Division; Partial Owner

### Project #7

**Other Sponsored Activity Agreement between the University and Refraction AI, Inc.  
Reviewed by the UMOR Conflict of Interest Review Committee**

#### Project Information

**Title:** Refraction AI 311 MSCM MAP 2023

**U-M Project ID:** 23-PAF04111

**Direct Sponsor:** Refraction AI, Inc.

**Principal Investigator/Department:** Chris Tarnacki, Ross School of Business Action Based Learning

**Project Duration:** Nine (9) Months

**Funding Support:** \$5,000

**Purpose:** The purpose of this activity is to examine Refraction AI, Inc.'s current and projected robotics supply chain for risks and make recommendations in a 3-year plan to support scaling up the business across the U.S. market.

#### University Employee; University Title; Relationship with Refraction AI, Inc.

- Ram Vasudevan; Associate Professor, Robotics; Partial Owner

### Project #8

**Subcontract Agreement between the University and Taza Aya Inc. (formerly known as Taza Aya LLC)  
Reviewed by the UMOR Conflict of Interest Review Committee**

#### Project Information

**Title:** Toward a More Resilient Domestic Food Infrastructure: Protecting Workers from Communicable Diseases During Meat and Poultry Processing

**U-M Project ID:** 23-PAF02726

**Direct Sponsor:** Taza Aya Inc.

**Prime Sponsor:** US Department of Agriculture

**Principal Investigator/Department:** Alex Szczuka, Civil and Environmental Engineering

**Project Duration:** Two (2) Years

**Funding Support:** \$220,070

**Purpose:** The purpose of this project is to analyze aliquots taken from samples in which viral aerosols before and after plasma treatment have been collected.

#### University Employee; University Title; Relationship with Taza Aya Inc.

- Herek Clack; Associate Professor, Civil and Environmental Engineering; Partial Owner
- Michael Drake; Senior Executive Director, Office of Advancement–College of Engineering; Partial Owner

**Project #9**

**Other Sponsored Activity Agreement between the University and Taza Aya Inc.  
Reviewed by the UMOR Conflict of Interest Review Committee**

**Project Information**

**Title:** Plasma driven inactivation of bacteriophage MS2

**U-M Project ID:** 23-PAF03738

**Direct Sponsor:** Taza Aya Inc.

**Principal Investigator/Department:** Alex Szczuka, Civil and Environmental Engineering

**Project Duration:** One (1) Year

**Funding Support:** \$18,753

**Purpose:** The purpose of this activity is to evaluate and optimize the removal of bacteriophage MS2 by a novel plasma device and assay samples provided by Taza Aya Inc. for MS2 inactivation.

**University Employee; University Title; Relationship with Taza Aya Inc.**

- Herek Clack; Associate Professor, Civil and Environmental Engineering; Partial Owner
- Michael Drake; Senior Executive Director, Office of Advancement–College of Engineering; Partial Owner